Animal Rule's Study Designs For Anthrax Vaccine Show Utility For Other Products
Executive Summary
When an FDA advisory panel gave its enthusiastic backing to the strategy for anthrax vaccine research developed by the agency's Center for Biologics Evaluation and Research, it also provided an important precedent for future applications of the "animal rule," which allows sponsors to conduct animal trials when human clinical trials would be impractical or unethical.
You may also be interested in...
Smallpox Treatments: Are Monkeypox Or Mousepox Acceptable Substitutes For Studying The Virus?
Smallpox has been eradicated for more than 30 years, but FDA isn't sure whether sponsors studying treatments in animals in case terrorists deliberately infected people can use substitute pathogens under the “Animal Rule.” The Antiviral Drugs Advisory Committee will weigh in on the issue.
FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill
Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.
FDA “Progressive Approval” And “Exceptional Approval” Pathways Possible Under Senate Bill
Legislation being drafted by Sen. Kay Hagan, D-N.C., would formalize FDA practices of approving drugs in certain circumstances where the evidence needed for a standard approval cannot be generated.